Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AADI NASDAQ:EGRX OTCMKTS:MRVFF NASDAQ:PYRGF On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAADIAadi Bioscience$1.70-2.3%$1.85$1.21▼$3.81$41.99M0.68261,100 shs12,034 shsEGRXEagle Pharmaceuticals$3.19$3.21$1.50▼$3.87$41.43M0.836,795 shs1 shsMRVFFNuvo Pharmaceuticals$0.98$0.98$0.42▼$1.25$11.17M0.9811,250 shsN/APYRGFPyroGenesis Canada$0.22+2.4%$0.30$0.21▼$0.71$41.33M0.8313,089 shs500 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAADIAadi Bioscience0.00%+8.75%-10.77%-1.14%+10.13%EGRXEagle Pharmaceuticals0.00%-0.31%-13.55%+63.59%-30.04%MRVFFNuvo Pharmaceuticals0.00%0.00%0.00%0.00%0.00%PYRGFPyroGenesis Canada-3.93%-11.14%-27.26%-35.54%-64.40%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAADIAadi Bioscience0.4273 of 5 stars1.00.00.00.00.02.51.3EGRXEagle PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AMRVFFNuvo PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/APYRGFPyroGenesis CanadaN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAADIAadi Bioscience 2.00Hold$1.752.94% UpsideEGRXEagle Pharmaceuticals 0.00N/AN/AN/AMRVFFNuvo Pharmaceuticals 0.00N/AN/AN/APYRGFPyroGenesis Canada 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAADIAadi Bioscience$25.07M1.67N/AN/A$4.29 per share0.40EGRXEagle Pharmaceuticals$257.55M0.16$7.98 per share0.40N/A∞MRVFFNuvo Pharmaceuticals$54.98M0.20$0.09 per share11.09($0.80) per share-1.22PYRGFPyroGenesis Canada$9.14M4.52N/AN/A($0.01) per share-22.04Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAADIAadi Bioscience-$65.76M-$2.35N/AN/AN/A-246.06%-71.87%-57.28%11/4/2025 (Estimated)EGRXEagle Pharmaceuticals$35.64MN/A0.00∞N/AN/AN/AN/AN/AMRVFFNuvo Pharmaceuticals-$25.70M-$0.12N/A∞N/A20.88%-1,996.22%14.25%N/APYRGFPyroGenesis Canada-$21.12M-$0.03N/A∞N/A-115.14%N/A-60.81%N/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAADIAadi BioscienceN/AN/AN/AN/AN/AEGRXEagle PharmaceuticalsN/AN/AN/AN/AN/AMRVFFNuvo PharmaceuticalsN/AN/AN/AN/AN/APYRGFPyroGenesis CanadaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAADIAadi BioscienceN/A4.894.54EGRXEagle PharmaceuticalsN/AN/AN/AMRVFFNuvo Pharmaceuticals9.972.111.77PYRGFPyroGenesis CanadaN/A0.600.50Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAADIAadi Bioscience52.08%EGRXEagle Pharmaceuticals85.36%MRVFFNuvo PharmaceuticalsN/APYRGFPyroGenesis Canada0.03%Insider OwnershipCompanyInsider OwnershipAADIAadi Bioscience37.30%EGRXEagle Pharmaceuticals28.90%MRVFFNuvo Pharmaceuticals7.00%PYRGFPyroGenesis Canada47.68%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAADIAadi Bioscience4024.70 million15.49 millionOptionableEGRXEagle Pharmaceuticals10012.99 million9.23 millionNo DataMRVFFNuvo Pharmaceuticals10011.40 million10.60 millionNot OptionablePYRGFPyroGenesis Canada90187.53 million96.34 millionNo DataMRVFF, PYRGF, EGRX, and AADI HeadlinesRecent News About These CompaniesPyroGenesis Announces Second Quarter 2025 ResultsAugust 6, 2025 | globenewswire.comPyroGenesis Signs Additional Contract with Constellium to Advance Aluminum Furnace Electrification Using Plasma Torch TechnologyAugust 5, 2025 | globenewswire.comPyroGenesis Canada (NASDAQ:PYRGF) Stock Price Down 1% - Here's What HappenedAugust 3, 2025 | marketbeat.comPyroGenesis Schedules Second Quarter 2025 Financial Results and Business Update Conference CallAugust 1, 2025 | globenewswire.comPyroGenesis Receives Initial Contract for Titanium Metal Powder from European Additive Manufacturing CompanyJuly 31, 2025 | globenewswire.comPyroGenesis Confirms Third-Party SEM Analysis Supports Pilot-Scale Fumed Silica Morphology Consistent with Commercial-Grade Fumed SilicaJuly 28, 2025 | globenewswire.comPyroGenesis Announces Completion of Coke-Oven Gas Valorization and Hydrogen Production Project for Tata SteelJuly 15, 2025 | globenewswire.comPyroGenesis Improves Fumed Silica Quality, Purity, and Consistency Across Multiple Production CyclesJuly 8, 2025 | globenewswire.comPyroGenesis Signs $600,000 Contract Targeting Plastic Waste Management Problem in EuropeJuly 2, 2025 | globenewswire.comPyroGenesis Reports Voting Results from 2025 Annual Meeting of Shareholders - MorningstarJune 29, 2025 | morningstar.comMPyroGenesis Reports Voting Results from 2025 Annual Meeting of ShareholdersJune 27, 2025 | globenewswire.comPyroGenesis Confirms Verification of Fumed Silica Samples by Leading Global SupplierJune 12, 2025 | globenewswire.comPyroGenesis Announces Extension to Term of WarrantsJune 9, 2025 | globenewswire.comHigh-Tech Micro Cap Rallies After Securing Boeing Supplier StatusMay 29, 2025 | msn.comPyroGenesis Confirms Receiving Accelerated Customer Request for Fumed Silica SamplesMay 28, 2025 | globenewswire.comPyroGenesis Confirms Production of Fumed Silica at Pilot Scale Following Independent AnalysisMay 21, 2025 | globenewswire.comPyroGenesis Confirms Successful Collection of Material from Fumed Silica Pilot Plant BaghouseMay 15, 2025 | globenewswire.comPyroGenesis, Inc. (PYRGF) Q1 2025 Earnings Call TranscriptMay 14, 2025 | seekingalpha.comPyroGenesis Announces First Quarter 2025 ResultsMay 13, 2025 | globenewswire.comPyroGenesis Provides Update on Fumed Silica ProjectMay 13, 2025 | globenewswire.comPyroGenesis Closes $2,385,000 First Tranche in Previously Announced LoanMay 12, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMRVFF, PYRGF, EGRX, and AADI Company DescriptionsAadi Bioscience NASDAQ:AADI$1.70 -0.04 (-2.30%) As of 08/25/2025Aadi Bioscience, Inc., a biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug product candidate comprises FYARRO, a form of sirolimus protein-bound particles for injectable suspension for the treatment in adult patients with advanced unresectable or metastatic malignant PEComa. The company is also involved in evaluating FYARRO in cancers, including indications targeting specific genomic alterations that activate the mTOR pathway. Aadi Bioscience, Inc. was incorporated in 2007 and is headquartered in Pacific Palisades, California.Eagle Pharmaceuticals NASDAQ:EGRX$3.19 0.00 (0.00%) As of 08/25/2025Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. Its product candidates also include EP-4104, a dantrolene sodium to treat organophosphate exposure; PEMFEXY, a ready-to-use/dilute liquid form of pemetrexed for non-small cell lung cancer and mesothelioma; EA-114 (fulvestrant) for HR+/HER- breast cancer; and Vasopressin injection, which is indicated to enhance blood pressure in adults with vasodilatory shock. The company has license and collaboration agreements with Combioxin, SA for the development and commercialization rights to CAL02, an antitoxin agent for the treatment of severe pneumonia in combination with traditional antibacterial drugs; and AOP Orphan Pharmaceuticals GmbH for the commercial rights of Landiolol, a novel therapeutic product candidate for the short-term reduction of ventricular rate in patients with supraventricular tachycardia, including atrial fibrillation and atrial flutter. It has a strategic collaboration with Tyme Technologies, Inc. for the development of SM-88 to treat breast cancer (HR+/HER2-) and high-risk metastatic sarcomas. Eagle Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Woodcliff Lake, New Jersey.Nuvo Pharmaceuticals OTCMKTS:MRVFF$0.98 0.00 (0.00%) As of 03/16/2023Nuvo Pharmaceuticals, Inc. is a pharmaceutical company, which is engaged in developing innovative therapeutic pharmaceutical products. It operates through the following segments: Commercial Business, Production and Service Business, and Licensing and Royalty Business. The Commercial Business segment includes Blexten, Cambia, the canadian business for Resultz and Suvexx, and mature assets. The Production and Service Business segment supplies Pennsaid to Horizon for the U.S. market and is engaged in ongoing partnering efforts for Pennsaid. The Licensing and Royalty Business segment engages in the selling of Vimovo. The company was founded on August 22, 1983 and is headquartered in Mississauga, Canada.PyroGenesis Canada NASDAQ:PYRGF$0.22 +0.01 (+2.37%) As of 03:45 PM EasternPyroGenesis Canada Inc. designs, develops, manufactures, and commercializes plasma processes and solutions worldwide. The company offers DROSRITE, a process for enhancing metal recovery from dross without any hazardous by-products; plasma atomization process that allows produce and sell high purity spherical metal powders; PUREVAP, a process to produce high purity metallurgical and solar grade silicon from quartz; and PUREVAP NSiR, which is designed to transform silicon into spherical silicon nano powders and nanowires for use in lithium-ion batteries. It provides plasma torches and plasma torch systems used toreplace fossil fuel burners in industrial iron ore pelletization process; plasma arc waste destruction systems for waste destruction onboard ships; steam plasma arc refrigerant cracking systems for the destruction of certain refrigerants, including chlorofluorocarbons, hydrofluorocarbons, and hydrochlorofluorocarbons; plasma arc chemical warfare agent destruction systems, which are mobile platforms for the onsite destruction of chemical warfare agents; plasma resource recovery systems for land-based waste destruction and waste-to-energy applications; plasma torches for waste gasification and combustion; and plasma arc gasification and vitrification. In addition, it offers engineering and manufacturing expertise, and contract research, as well as turnkey process equipment packages to the defense, metallurgical, mining, additive manufacturing (including 3D printing), oil and gas, and environmental industries. Further, the company provides installation, commissioning, and start-up services. PyroGenesis Canada Inc. is headquartered in Montreal, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Buffett’s Wisdom Could Spell Trouble for Palantir Shorts Tesla Just Had Its Best Day in 2 Months—Here’s What It Means Reynolds Consumer Products Stock Price: Insiders Signal a Bottom Ubiquiti's 30% Jump: Why This Was a Turnaround, Not Just a Trend Petrobras: Why Traders Are Betting Big on a Shareholder Payout Southern Company: From Nuclear Risk to AI Reward BJ’s Wholesale Club Pulls Back to Trend: It’s Time for an Entry Why Sprouts Farmers Market is Buying $1 Billion of Its Own Stock Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access